Retatrutide: The Complete Guide to Eli Lilly's Triple-Agonist Weight-Loss Drug (2026)

A new weight-loss drug is generating more clinical excitement than anything since Ozempic — and it hasn't even been approved yet. Retatrutide, developed by Eli Lilly, has produced the highest weight loss ever recorded for a medication in its class, with Phase 3 trial data showing an average of 28.7% body weight loss at 68 weeks. For context, that rivals bariatric surgery.

But what exactly is retatrutide, how does it work, and when can patients actually get it? This guide covers everything you need to know, based on the latest clinical data as of 2026.

What Is Retatrutide?

Retatrutide (drug code: LY3437943) is an investigational weight-loss and metabolic drug developed by the American pharmaceutical company Eli Lilly. It is currently in phase 3 clinical trials under Eli Lilly's TRIUMPH program—the final stage of testing required before a drug can be submitted to the FDA for approval.

It is not yet FDA-approved, cannot be legally prescribed, and is not available at pharmacies. The only legal way to access retatrutide today is through enrollment in a clinical trial.

What makes retatrutide unique—and why it has captured the attention of obesity medicine specialists worldwide—is its mechanism. Unlike any currently approved weight-loss drug, retatrutide is a triple agonist: it simultaneously activates three hormone receptors in the body, producing a level of metabolic impact that single- and dual-agonist drugs cannot match. Visit here 

How Retatrutide Works: The Triple-Agonist Mechanism

To understand retatrutide, it helps to understand the drugs that came before it.

Semaglutide (Ozempic, Wegovy) works by activating one receptor: GLP-1. It reduces appetite, slows digestion, and improves insulin sensitivity. It was considered a breakthrough when it showed roughly 15% average weight loss in clinical trials.

Tirzepatide (Mounjaro and Zepbound) added a second receptor—GIP—on top of GLP-1. This dual-agonist approach improved results to around 21% average weight loss, making it the current gold standard among approved medications.

Retatrutide adds a third receptor: glucagon (GCGR). This is where the drug gets genuinely novel.

GLP-1 receptor: appetite and insulin control

GLP-1 receptor activation reduces hunger signals in the brain, slows gastric emptying so you feel full longer, and improves how the body secretes and responds to insulin. This is the well-established mechanism shared by semaglutide and tirzepatide.

GIP receptor: energy metabolism and fat storage

GIP receptor agonism amplifies the insulin response and appears to enhance the metabolic effects of GLP-1 in a synergistic way. It also reduces nausea at higher doses — counterintuitive, but well-documented in tirzepatide trials. Retatrutide includes this dual action as its baseline.

Glucagon receptor: the fat-burning third layer

Glucagon is traditionally thought of as the hormone that raises blood sugar — the "anti-insulin." But at the doses used in retatrutide's trials, activating the glucagon receptor does something different: it increases resting energy expenditure and drives the liver to burn stored fat directly. In simpler terms, it turns up the body's metabolic engine. This is the mechanism responsible for retatrutide's superior results over both semaglutide and tirzepatide.

Clinical Trial Results: What the Data Shows

Phase 2 results (NEJM, 2023)

The first major efficacy data came from a Phase 2 trial published in the New England Journal of Medicine in 2023. Adults with obesity but without type 2 diabetes were treated with retatrutide over 48 weeks. Participants on the highest dose lost an average of 24.2% of their body weight — the highest ever recorded for a GLP-1 class drug at that point.

Beyond weight loss, participants also saw approximately a 20% reduction in LDL cholesterol and up to 82% reduction in liver fat in related trials, suggesting broad metabolic benefits well beyond the scale.

TRIUMPH Phase 3: raising the bar further

Eli Lilly's TRIUMPH program includes eight Phase 3 trials evaluating retatrutide across multiple conditions—obesity, type 2 diabetes, cardiovascular disease, fatty liver disease (NASH), and knee osteoarthritis.

The first Phase 3 results, from TRIUMPH-4, were announced in December 2025. Participants on the 12 mg dose lost an average of 28.7% of their body weight (approximately 71 lbs / 32 kg) over 68 weeks. Seven additional TRIUMPH trial readouts are expected throughout 2026.

Retatrutide vs Semaglutide vs Tirzepatide

Here's how the three drugs compare based on available clinical trial data:

Side Effects: What to Expect

Retatrutide's side effect profile is consistent with the broader GLP-1 drug class. The most commonly reported adverse events in trials are gastrointestinal: nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. These effects are typically mild to moderate and most pronounced during dose escalation.

One additional signal unique to retatrutide is a transient increase in heart rate, attributed to the glucagon receptor component. This peaked at around 24 weeks in Phase 2 participants and declined thereafter — a pattern consistent with other glucagon-based therapies.

FDA Approval Timeline: When Will Retatrutide Be Available?

As of April 2026, retatrutide has not yet been submitted to the FDA. Eli Lilly is expected to submit a New Drug Application (NDA) in Q4 2026 or Q1 2027, once the remaining TRIUMPH trial results are compiled and analyzed.

The FDA's standard review process takes approximately 10 months. That puts potential approval in late 2027, with realistic commercial availability—prescription access, pharmacy stocking, and insurance negotiations—landing in Q1–Q2 2028.

This timeline assumes no major safety findings emerge from remaining trials and that the review proceeds at a standard pace.

What you can do now:

• Check ClinicalTrials.gov to see if a TRIUMPH trial is enrolling near you

• Speak to your doctor about currently approved options (tirzepatide or semaglutide) if you're managing obesity or type 2 diabetes today

• Be cautious of any website claiming to sell retatrutide — no legitimate source exists outside of regulated clinical trials

Frequently Asked Questions

Is retatrutide FDA-approved? No. As of April 2026, it remains an investigational drug in Phase 3 trials. FDA submission is expected late in 2026, with approval potentially following in late 2027.

How much weight can you lose on retatrutide? Phase 3 data shows an average of 28.7% body weight loss at 68 weeks—approximately 71 lbs on the highest dose. This approaches the outcomes seen with bariatric surgery.

What makes retatrutide different from Ozempic? Retatrutide activates three hormone receptors (GLP-1, GIP, and glucagon) versus semaglutide's one (GLP-1). The added glucagon receptor activation increases energy expenditure and fat burning in a way semaglutide cannot replicate.

The Bottom Line

Retatrutide represents a genuine step change in obesity medicine. The trial data is compelling, the mechanism is novel, and if the remaining TRIUMPH results hold up, it will arrive as the most effective non-surgical weight-loss treatment ever approved.

But it isn't here yet. For anyone managing obesity or metabolic disease today, the practical advice remains the same: work with a clinician, explore currently approved options, and watch this space closely for 2027 approval news.